Study details
Enrolling now
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Christian Hinrichs
NCT IDNCT05483491ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
30
Study length
about 6.3 years
Ages
18+
Locations
2 sites in NJ
About this study
This trial is testing the safety of KK-LC-1 TCR-T cells in people with advanced cancers that express KK-LC-1. Participants will receive a treatment regimen including KK-LC-1 TCR-T cells, aldesleukin, and a conditioning regimen. The goal is to determine the maximum dose of this treatment and assess its effects on the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive KK-LC-1 TCR-T cells
- 2.Take Aldesleukin
PhasePhase 1
DrugAldesleukin
Primary goalMaximum tolerated dose (MTD) of KK-LC-1 TCR-T cells
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
aldesleukin
Endpoints
Primary: Maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells
Secondary: Adverse events of KK-LC-1 TCR T cells, Tumor response rate
Body systems
Oncology